Cargando…

Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols

Variability in the subfertile patient population excludes the possibility of a single approach to controlled ovarian stimulation (COS) covering all the requirements of a patient. Modern technology has led to the development of new drugs, treatment options and quantitative methods that can identify s...

Descripción completa

Detalles Bibliográficos
Autores principales: Alviggi, Carlo, Humaidan, Peter, Ezcurra, Diego
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299595/
https://www.ncbi.nlm.nih.gov/pubmed/22309877
http://dx.doi.org/10.1186/1477-7827-10-9
_version_ 1782226127825141760
author Alviggi, Carlo
Humaidan, Peter
Ezcurra, Diego
author_facet Alviggi, Carlo
Humaidan, Peter
Ezcurra, Diego
author_sort Alviggi, Carlo
collection PubMed
description Variability in the subfertile patient population excludes the possibility of a single approach to controlled ovarian stimulation (COS) covering all the requirements of a patient. Modern technology has led to the development of new drugs, treatment options and quantitative methods that can identify single patient characteristics. These could potentially be used to match patients with the right treatment options to optimise efficacy, safety and tolerability during COS. Currently, age and follicle-stimulating hormone (FSH) level remain the most commonly used single patient characteristics in clinical practice. These variables only provide a basic prognosis for success and indications for standard COS treatment based on gross patient categorisation. In contrast, the anti-Müllerian hormone level appears to be an accurate predictor of ovarian reserve and response to COS, and could be used successfully to guide COS. The antral follicle count is a functional biomarker that could be useful in determining the dose of FSH necessary during stimulation and the success of treatment. Finally, in the future, genetic screening may allow an individual patient's response to stimulation during COS to be predicted based on genotype. Unfortunately, despite the predictive power of these measures, no single biomarker can stand alone as a guide to determine the best treatment option. In the future, hormonal, functional and genetic biomarkers will be used together to personalise COS.
format Online
Article
Text
id pubmed-3299595
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32995952012-03-13 Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols Alviggi, Carlo Humaidan, Peter Ezcurra, Diego Reprod Biol Endocrinol Review Variability in the subfertile patient population excludes the possibility of a single approach to controlled ovarian stimulation (COS) covering all the requirements of a patient. Modern technology has led to the development of new drugs, treatment options and quantitative methods that can identify single patient characteristics. These could potentially be used to match patients with the right treatment options to optimise efficacy, safety and tolerability during COS. Currently, age and follicle-stimulating hormone (FSH) level remain the most commonly used single patient characteristics in clinical practice. These variables only provide a basic prognosis for success and indications for standard COS treatment based on gross patient categorisation. In contrast, the anti-Müllerian hormone level appears to be an accurate predictor of ovarian reserve and response to COS, and could be used successfully to guide COS. The antral follicle count is a functional biomarker that could be useful in determining the dose of FSH necessary during stimulation and the success of treatment. Finally, in the future, genetic screening may allow an individual patient's response to stimulation during COS to be predicted based on genotype. Unfortunately, despite the predictive power of these measures, no single biomarker can stand alone as a guide to determine the best treatment option. In the future, hormonal, functional and genetic biomarkers will be used together to personalise COS. BioMed Central 2012-02-06 /pmc/articles/PMC3299595/ /pubmed/22309877 http://dx.doi.org/10.1186/1477-7827-10-9 Text en Copyright ©2012 Alviggi et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Alviggi, Carlo
Humaidan, Peter
Ezcurra, Diego
Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols
title Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols
title_full Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols
title_fullStr Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols
title_full_unstemmed Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols
title_short Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols
title_sort hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299595/
https://www.ncbi.nlm.nih.gov/pubmed/22309877
http://dx.doi.org/10.1186/1477-7827-10-9
work_keys_str_mv AT alviggicarlo hormonalfunctionalandgeneticbiomarkersincontrolledovarianstimulationtoolsformatchingpatientsandprotocols
AT humaidanpeter hormonalfunctionalandgeneticbiomarkersincontrolledovarianstimulationtoolsformatchingpatientsandprotocols
AT ezcurradiego hormonalfunctionalandgeneticbiomarkersincontrolledovarianstimulationtoolsformatchingpatientsandprotocols